Centre de Reference Maladie de Marfan Et Apparente
Paris, Île-de-France Region, 75018, France
NCT Number: NCT01707563
Marfan syndrome is an autosomal dominant connective tissue disorder caused by mutations in the fibrillin-1 gene (FBN1). Penetrance of FBN1 mutations is complete but intra and inter familial clinical expressivity is extremely variable. The underlying mechanisms for variability are not understood. An interesting mechanism is that the expression level of the wild type and/or mutated allele may play a role in the determination of variability.
Principal objective: To evaluate in Marfan patients, if FBN1 expression level (non-mutated or mutated allele) modulates the clinical expression of the disease.
Judgment criteria : Correlation allelic expression level-phenotype Perspectives : To search the predictive factors of severity in order to ameliorate precocity of taking care.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Paris, Île-de-France Region, 75018, France
Marfan syndrome is an autosomal dominant connective tissue disorder caused by mutations in the fibrillin-1 gene (FBN1). Penetrance of FBN1 mutations is complete but intra and inter familial clinical expressivity is extremely variable. The underlying mechanisms for variability are not understood. An interesting mechanism is that the expression level of the wild type and/or mutated allele may play a role in the determination of variability.
Principal objective : To evaluate in Marfan patients, if FBN1 expression level (non-mutated or mutated allele) modulates the clinical expression of the disease in individuals from families with clinical variability (intrafamilial) and in independant probands (interfamilial).
Judgment criteria : Correlation allelic expression level-phenotype Method : In Marfan patients with a FBN1 nul allele, FBN1 RNA will be extracted from a fibroblast culture. Allelic FBN1 expression level will be performed by quantitative RT-PCR and then compared with clinical evaluation.
Number of subjects : 160 subjects, 45 Marfan patients in 15 independent families, 5 patients with the same mutation, 30 with a private mutation leading to a nul allele and 80 non Marfan subjects.
Perspectives : To search the predictive factors of severity in order to ameliorate precocity of taking care.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-No affiliated to a Healthcare System.
Time frame: 6 months
Evaluation in Marfan patients, of FBN1 expression level (non-mutated or mutated allele) compared to the clinical expression of the disease in idividuals
Assistance Publique - Hôpitaux de Paris
Other
Correlations' Study Between Variability of Expression in FBN1 Gene and Clinical Features in Marfan Patients.
Acronym: Variarfan
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05123339
Abnormalities, Multiple, Arachnodactyly
Paris, IDF, France
View Trial DetailsNCT02111668
Abnormalities, Multiple, Arachnodactyly
Aarhus, Central Jutland, Denmark
View Trial DetailsNCT00001641
Abnormalities, Multiple, Acute Aortic Syndrome
Bethesda, Maryland, United States
View Trial DetailsNCT04776681
Abnormalities, Multiple, Bone Diseases
London, United Kingdom
View Trial Details